Use of sodium–glucose cotransporter 2 inhibitor in heart failure: a real-world study

View Full Paper

Ask AI

Bookmark

Authors

Discussion

Real-world evidence shows SGLT2i adherence in heart failure patients, suggesting effective management for high comorbidity burden.

High adherence noted among heart failure patients taking SGLT2 inhibitors, enhancing treatment effectiveness.
Study indicates similar adherence levels compared to data from other real-world evidence studies.
Analysis of SGLT2i use in patients with heart failure and significant comorbidities was conducted to assess treatment impact.
Findings support the effective integration of SGLT2i in managing heart failure with associated comorbid conditions.

Lerma-Barco et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark